XTL BIOPHARMACEUTICALS-ADR (XTLB) Stock Overview
USA - NASDAQ:XTLB - US98386D3070 - ADR
XTLB Key Statistics, Chart & Performance
The current stock price of XTLB is 1.23 USD. In the past month the price increased by 5.13%. In the past year, price decreased by -20.65%.
XTLB Latest News, Press Relases and Analysis
XTLB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.76B | ||
| AMGN | AMGEN INC | 13.38 | 157.07B | ||
| GILD | GILEAD SCIENCES INC | 15.63 | 150.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.75B | ||
| ARGX | ARGENX SE - ADR | 88.74 | 50.32B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.02 | 34.14B | ||
| INSM | INSMED INC | N/A | 33.75B | ||
| NTRA | NATERA INC | N/A | 26.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.40B | ||
| BIIB | BIOGEN INC | 9.36 | 21.98B |
Related stock screener links
About XTLB
Company Profile
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The firm pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong a survival of patients for treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by kidneys. EPO stimulates erythropoiesis, production of red blood cells, by binding to its receptor on a surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.
Company Info
XTL BIOPHARMACEUTICALS-ADR
5 Badner St., P.O.Box 8241
Ramat Gan 4365603 IL
CEO: Shlomo Shalev
Employees: 33
Phone: 97299557080
XTL BIOPHARMACEUTICALS-ADR / XTLB FAQ
What does XTL BIOPHARMACEUTICALS-ADR do?
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The firm pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong a survival of patients for treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by kidneys. EPO stimulates erythropoiesis, production of red blood cells, by binding to its receptor on a surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.
What is the current price of XTLB stock?
The current stock price of XTLB is 1.23 USD. The price decreased by -0.81% in the last trading session.
Does XTLB stock pay dividends?
XTLB does not pay a dividend.
What is the ChartMill rating of XTL BIOPHARMACEUTICALS-ADR stock?
XTLB has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Is XTL BIOPHARMACEUTICALS-ADR (XTLB) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on XTLB.
What is the employee count for XTLB stock?
XTL BIOPHARMACEUTICALS-ADR (XTLB) currently has 33 employees.
What is the market capitalization of XTLB stock?
XTL BIOPHARMACEUTICALS-ADR (XTLB) has a market capitalization of 10.84M USD. This makes XTLB a Nano Cap stock.
XTLB Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to XTLB. When comparing the yearly performance of all stocks, XTLB is a bad performer in the overall market: 90.44% of all stocks are doing better.
XTLB Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |